Phaseline

Companies › IGC Pharma

IGC Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IGC-AD1
Delta-9-tetrahydrocannabinol (THC)
CNR1, CNR2Phase 2Alzheimer DiseaseNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05543681IGC-AD1Phase 2Alzheimer DiseaseNeurologyNov 2026

From the company's SEC filings

Cash and short-term investments of $0m on 2026-09-30; operating cash outflow about $5m a year; runway about 1 months at that burn, to Oct 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

CNR1 (1) CNR2 (1)

Companies with the same targets

Zynerba Pharmaceuticals Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

NeuroTherapia Larimar Therapeutics Satellos Bioscience Coya Therapeutics PepGen

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.